Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year - CNBC
- Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year CNBC
- Weight-Loss Drug Zepbound Offers a New Way to Treat Sleep Apnea The New York Times
- Mounjaro Drug Tirzepatide Could Treat Sleep Apnea, Study Finds Forbes
- Eli Lilly seeks FDA’s OK to expand Zepbound’s uses to include sleep apnea MarketWatch
- Weight-Loss Drug Zepbound Resolves Sleep Apnea in up to 52% of Patients, Lilly Says U.S. News & World Report